Sydnexis, Inc. Advances SYD-101 Data in Myopia Trial
DEL MAR, California, May 1, 2026 Sydnexis, Inc. announced it will present new Phase 3 STAR trial data for...
Clinical Research
Advertisement
Larimar Therapeutics Validates Skin Biomarker in FA
BALA CYNWYD, Pennsylvania, April 30, 2026 Larimar Therapeutics, Inc. announced the publication of new cross-species research supporting the use...
Neurocrine Defines TDIS Threshold for TD Treatment Impact
SAN DIEGO, California, April 29, 2026 Neurocrine Biosciences announced the publication of new peer-reviewed research in The Journal of...
Paradigm Health, FDA Advance Real-Time Trial Review Model
WASHINGTON & COLUMBUS, OHIO, April 28, 2026 Paradigm Health has announced a landmark research collaboration with the U.S. Food...
Vanda Pharma Publishes Phase III Imsidolimab Data
WASHINGTON, April 28, 2026 Vanda Pharmaceuticals Inc. has announced the publication of pivotal Phase III clinical data evaluating imsidolimab,...
Advertisements
Boehringer Survodutide Shows 16.6% Weight Loss in Phase III
INGELHEIM, GERMANY, April 28, 2026 Boehringer Ingelheim has announced positive Phase III results for its investigational dual agonist survodutide,...
OrthoTrophix TPX-100 Shows Breakthrough in Knee OA Study
Foster City, California | April 24, 2026 OrthoTrophix has unveiled compelling new clinical findings highlighting the structural relationship between...
Astellas and Pfizer Gain FDA Priority Review for PADCEV Combo
TOKYO, Japan and NEW YORK, U.S., April 20, 2026 Astellas Pharma Inc. and Pfizer Inc. have announced that the...
Nektar Rezpegaldesleukin Shows 52-Week Alopecia Results
SAN FRANCISCO, April 20, 2026 Nektar Therapeutics has reported compelling 52-week topline results from the Phase 2b REZOLVE-AA trial,...
AstraZeneca Reports Phase III Success for Tozorakimab in COPD
CAMBRIDGE, United Kingdom, April 20, 2026 AstraZeneca has reported positive results from its pivotal Phase III MIRANDA trial, demonstrating...
Advertisement
